Engineering Nanomedicine for Non-Viral RNA-Based Gene Therapy of Glioblastoma
Open Access
- 1 April 2024
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (4) , 482
Abstract
Glioblastoma multiforme (GBM) is the most common type of malignant tumor of the central nervous system, characterized by aggressiveness, genetic instability, heterogenesis, and unpredictable clinical behavior. Disappointing results from the current clinical therapeutic methods have fueled a search for new therapeutic targets and treatment modalities. GBM is characterized by various genetic alterations, and RNA-based gene therapy has raised particular attention in GBM therapy. Here, we review the recent advances in engineered non-viral nanocarriers for RNA drug delivery to treat GBM. Therapeutic strategies concerning the brain-targeted delivery of various RNA drugs involving siRNA, microRNA, mRNA, ASO, and short-length RNA and the therapeutical mechanisms of these drugs to tackle the challenges of chemo-/radiotherapy resistance, recurrence, and incurable stem cell-like tumor cells of GBM are herein outlined. We also highlight the progress, prospects, and remaining challenges of non-viral nanocarriers-mediated RNA-based gene therapy.Keywords
Funding Information
- National Natural Science Foundation of China (32101152, 2023M741014, 242300420457, 232102230092, 202310475002)
- China Postdoctoral Science Foundation (32101152, 2023M741014, 242300420457, 232102230092, 202310475002)
- Youth Fund of the Henan Natural Science Foundation (32101152, 2023M741014, 242300420457, 232102230092, 202310475002)
- Key Technologies R & D Program of Henan (32101152, 2023M741014, 242300420457, 232102230092, 202310475002)
- Key Support Areas Project of the Innovation and Entrepreneurship Training Program for China University Students (32101152, 2023M741014, 242300420457, 232102230092, 202310475002)
This publication has 66 references indexed in Scilit:
- mRNA nanomedicine: Design and recent applicationsExploration, 2022
- Brain Co‐Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma ChemotherapyAdvanced Materials, 2022
- Synchronous Disintegration of Ferroptosis Defense Axis via Engineered Exosome‐Conjugated Magnetic Nanoparticles for Glioblastoma TherapyAdvanced Science, 2022
- Cation‐Free siRNA Micelles as Effective Drug Delivery Platform and Potent RNAi Nanomedicines for Glioblastoma TherapyAdvanced Materials, 2021
- Contemporary RNA Therapeutics for GlioblastomaNeuroMolecular Medicine, 2021
- The Multifaceted Glioblastoma: From Genomic Alterations to Metabolic Adaptations2021
- Hypoxia‐induced cofilin 1 promotes hepatocellular carcinoma progression by regulating the PLD1/AKT pathwayClinical and Translational Medicine, 2021
- siRNA Nanoparticle Suppresses Drug‐Resistant Gene and Prolongs Survival in an Orthotopic Glioblastoma Xenograft Mouse ModelAdvanced Functional Materials, 2020
- Long noncoding RNA MALAT1 promotes brain metastasis by inducing epithelial-mesenchymal transition in lung cancerJournal of Neuro-Oncology, 2014
- Short Hairpin RNA (shRNA): Design, Delivery, and Assessment of Gene Knockdown2010